Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Collaboration by Quarter
CRISPR Collaboration — Vertex share of program development costs (%) (%)
Vertex Pharmaceuticals CRISPR Collaboration: 4,000.0% in Q2 2026, unchanged from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR JDCA).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Collaboration — Vertex share of program development costs (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 4,000.0% | 0.0 pts | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 4,000.0% | 0.0 pts | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,000.0% | 0.0 pts | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 4,000.0% | 0.0 pts | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 4,000.0% | 0.0 pts | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,000.0% | 0.0 pts | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,000.0% | 0.0 pts | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,000.0% | – | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,000.0% | – | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,000.0% | – | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 4,000.0% | – | Form 10-K (filed 2024-02-15) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Collaboration (%), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/collab-rd-pct-crispr
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.